Positron emission tomography (PET) of brain amyloid β is a technology that is becoming
more available, but its clinical utility in medical practice requires careful definition. To …

Aging, hypertension, diabetes, hypoxia/obstructive sleep apnea (OSA), obesity, vitamin
B12/folate deficiency, depression, and traumatic brain injury synergistically promote diverse …

Despite the best available medical treatments, many patients continue to be disabled by
neurologic and psychiatric disorders, resulting in a large unmet need. Advances in imaging …

Lower brain glucose metabolism is present before the onset of clinically measurable
cognitive decline in two groups of people at risk of Alzheimer's disease---carriers of …

Currently, over five million Americans suffer with Alzheimer's disease (AD). In the absence of
a cure, this number could increase to 13.8 million by 2050. A critical goal of biomedical …

These guidelines summarize the current views of the European Association of Nuclear
Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist …

In Alzheimer disease (AD), which is the most common cause of dementia, the underlying
disease pathology most probably precedes the onset of cognitive symptoms by many years …

Aims: Microglia are involved in neurodegeneration, are prime targets for anti‐inflammatory
therapy and are potential biomarkers of disease progression. For example, positron …

Dementia affects the patient's memory and leads to language impairment. Research has
demonstrated that speech and language deterioration is often a clear indication of dementia …

Network analysis of functional brain imaging data is an innovative approach to study circuit
abnormalities in neurodegenerative diseases. In Parkinson's disease, spatial covariance …